Drugs & Targets FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients April 03, 2026Vol.52 No.13
Clinical Roundup Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds March 27, 2026Vol.52 No.12
Clinical Roundup Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication March 20, 2026Vol.52 No.11
Clinical Roundup Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective March 13, 2026Vol.52 No.10
Cancer Policy Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members March 06, 2026Vol.52 No.09By Claire Marie Porter and Sara Willa Ernst
Clinical Roundup TNBC can become resistant to therapy in more than one way, Baylor study finds March 06, 2026Vol.52 No.09
Clinical Roundup Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds February 27, 2026Vol.52 No.08
In Brief Indiana University receives $5M grant to expand breast cancer diagnosis, care in Kenya February 20, 2026Vol.52 No.07
Clinical Roundup Exposure to pathogenic bacteria significantly increased SMOX activity, leading growth and metastasis of breast cancer, JHU-led study finds February 20, 2026Vol.52 No.07
Clinical Roundup NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer February 06, 2026Vol.52 No.05
